Oral formulation of angiotensin-(1-7) promotes therapeutic actions in a model of eosinophilic and neutrophilic asthma

Página do item simplificado
dc.creatorGiselle Santos Magalhães
dc.creatorJuliana Fabiana Gregório
dc.creatorArthur Tonani Pereira Cançado Ribeiro
dc.creatorIsis Felippe Baroni
dc.creatorAna Victoria de Oliveira Vasconcellos
dc.creatorGabriela Pansanato Nakashima
dc.creatorIsabel Fusaro Aguiar Oliveira
dc.creatorNatália Alves de Matos
dc.creatorThalles de Freitas Castro
dc.creatorFrank Silva Bezerra
dc.creatorRubén Dario Sinisterra Millán
dc.creatorVanessa Pinho
dc.creatorMauro Martins Teixeira
dc.creatorRobson Augusto Souza Santos
dc.creatorMaria da Glória Rodrigues-Machado
dc.creatorMaria José Campagnole dos Santos
dc.date.accessioned2023-12-12T17:49:29Z
dc.date.accessioned2025-09-09T00:23:30Z
dc.date.available2023-12-12T17:49:29Z
dc.date.issued2021
dc.description.sponsorshipCNPq - Conselho Nacional de Desenvolvimento Científico e Tecnológico
dc.description.sponsorshipFAPEMIG - Fundação de Amparo à Pesquisa do Estado de Minas Gerais
dc.description.sponsorshipCAPES - Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
dc.description.sponsorshipINCT – Instituto nacional de ciência e tecnologia (Antigo Instituto do Milênio)
dc.format.mimetypepdf
dc.identifier.doihttps://doi.org/10.3389/fphar.2021.557962
dc.identifier.issn1663-9812
dc.identifier.urihttps://hdl.handle.net/1843/61924
dc.languageeng
dc.publisherUniversidade Federal de Minas Gerais
dc.relation.ispartofFrontiers in Pharmacology
dc.rightsAcesso Aberto
dc.subjectFarmacologia pulmonar
dc.subjectAngiotensina
dc.subjectAsma
dc.subjectEosinófilos
dc.subjectNeutrófilos
dc.subjectAparelho respiratório -- Doenças
dc.subject.otherResolution of inflammation
dc.subject.otherEosinophilic inflammation
dc.subject.otherNeutrophilic inflammation
dc.subject.otherAllergic lung inflammation
dc.subject.otherLPS
dc.subject.otherRenin–angiotensin system 4
dc.titleOral formulation of angiotensin-(1-7) promotes therapeutic actions in a model of eosinophilic and neutrophilic asthma
dc.typeArtigo de periódico
local.citation.volume12
local.description.resumoThe presence of eosinophils and neutrophils in the lungs of asthmatic patients is associated with the severity of the disease and resistance to corticosteroids. Thus, defective resolution of eosinophilic and neutrophilic inflammation is importantly related to exacerbation of asthma. In this study, we investigated a therapeutic action of angiotensin-(1-7) (Ang-(1-7)) in a model of asthma induced by ovalbumin (OVA) and lipopolysaccharide (LPS). Balb-c mice were sensitized and challenged with OVA. Twenty-three hours after the last OVA challenge, experimental groups received LPS, and 1 h and 7 h later, mice were treated with oral formulation of Ang-(1-7). On the next day, 45 h after the last challenge with OVA, mice were subjected to a test of motor and exploratory behavior; 3 h later, lung function was evaluated, and bronchoalveolar lavage fluid (BALF) and lungs were collected. Motor and exploratory activities were lower in OVA + LPS-challenged mice. Treatment with Ang-(1-7) improved these behaviors, normalized lung function, and reduced eosinophil, neutrophil, myeloperoxidase (MPO), eosinophilic peroxidase (EPO), and ERK1/2 phosphorylation (p-ERK1/2) in the lungs. In addition, Ang-(1-7) decreased the deposition of mucus and extracellular matrix in the airways. These results extended those of previous studies by demonstrating that oral administration of Ang-(1-7) at the peak of pulmonary inflammation can be valuable for the treatment of neutrophil- and eosinophil-mediated asthma. Therefore, these findings potentially provide a new drug to reverse the natural history of the disease, unlike the current standards of care that manage the disease symptoms at best.
local.identifier.orcidhttps://orcid.org/0000-0002-2589-0332
local.identifier.orcidhttps://orcid.org/0000-0003-1032-4255
local.identifier.orcidhttps://orcid.org/0000-0002-6119-6049
local.identifier.orcidhttps://orcid.org/0000-0003-4486-1518
local.identifier.orcidhttps://orcid.org/0000-0002-5568-5997
local.identifier.orcidhttps://orcid.org/0000-0002-2535-2737
local.identifier.orcidhttps://orcid.org/0000-0001-8102-7720
local.identifier.orcidhttps://orcid.org/0000-0002-0804-5196
local.identifier.orcidhttps://orcid.org/0000-0001-7656-1849
local.identifier.orcidhttps://orcid.org/0000-0003-1038-2324
local.identifier.orcidhttps://orcid.org/0000-0002-6944-3008
local.identifier.orcidhttps://orcid.org/0000-0002-9950-1707
local.identifier.orcidhttps://orcid.org/0000-0001-9483-4206
local.publisher.countryBrasil
local.publisher.departmentICB - DEPARTAMENTO DE BIOQUÍMICA E IMUNOLOGIA
local.publisher.departmentICB - DEPARTAMENTO DE FARMACOLOGIA
local.publisher.departmentICB - DEPARTAMENTO DE FISIOLOGIA E BIOFÍSICA
local.publisher.departmentICB - DEPARTAMENTO DE MORFOLOGIA
local.publisher.departmentICX - DEPARTAMENTO DE QUÍMICA
local.publisher.initialsUFMG
local.url.externahttps://www.frontiersin.org/articles/10.3389/fphar.2021.557962/full

Arquivos

Pacote original

Agora exibindo 1 - 1 de 1
Imagem de Miniatura
Nome:
Oral formulation of angiotensin-(1-7) promotes therapeutic actions in a model of eosinophilic and neutrophilic asthma.pdf
Tamanho:
732.11 KB
Formato:
Adobe Portable Document Format
Baixar

Licença do pacote

Agora exibindo 1 - 1 de 1
Imagem de Miniatura
Nome:
License.txt
Tamanho:
1.99 KB
Formato:
Plain Text
Descrição:
Baixar

Coleções

Artigo de Periódico

Logo UFMG